Marwa EL Araby Shabana

Dr. Marwa EL Araby Shabana


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IHIngy M. Hashad
Ingy M. Hashad
SAShaza Hussiny Aly
Shaza Hussiny Aly
DDalia Saleh
Dalia Saleh
NENesma M. E. Abo El-Nasr
Nesma M. E. Abo El-Nasr
MSMarwa EL Araby Shabana
Marwa EL Araby Shabana
Ahmed M. MostafaAhmed M. Mostafa
Ahmed M. Mostafa
This study explores the metabolic profile and wound-healing capabilities of Ficus trijuja, a species within the Moraceae family, for the first time. Ficus plants contain a variety of secondary metabolites such as flavonoids, triterpenoids, and alkaloids, known for their antioxidant, anti-inflammatory, and cytotoxic properties. Previous studies demonstrated the effectiveness of Ficus extracts in wound healing, with evidence of improved wound contraction, strength, and faster epithelization. This study shows the impact of F. trijuja extract in a gel base as well as when delivered through a lipid nanocapsules (LNCs) formula, on all phases of wound-healing in rats, by determining the expression levels of their key markers. The results indicated that treatment with F. trijuja extract accelerated wound healing, particularly when applied through lipid nanocapsulation, which shows comparable efficacy to standard treatments like MEBO® with approximately 2.62% improvement in wound healing when compared to MEBO® itself. Understanding these molecular markers offers insights for developing targeted therapies to optimize wound healing and prevent complication development. To unravel the phytochemical composition of F. trijuja extract, LC-HRESIMS analysis was implemented, which revealed 24 secondary metabolites belonging to different classes of flavonoids, terpenoids, and megastigmane. In conclusion, both Ficus trijuja gel and its nanoformulation have proven efficacy in wound healing in vivo and can be further investigated for potential clinical use.

8 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WEWalaa A. El-dakroury
Walaa A. El-dakroury
SSSamar A. Salim
Samar A. Salim
ASAbdelrahman R. Said
Abdelrahman R. Said
GAGihan Asaad
Gihan Asaad
Mohamed Fayed abdelhameedMohamed Fayed abdelhameed
Mohamed Fayed abdelhameed
FEFatma Sa'eed EL-Tokhy
Fatma Sa'eed EL-Tokhy
Background/Objectives: Empagliflozin (EMPA) was repurposed for Alzheimer’s disease (AD) treatment via buccal delivery, exploiting novel nanofibers (NFs) integrating chitosan (Cs), silk fibroin (Fb), and poly(lactic acid) (PLA). Methods: EMPA-loaded Cs/Fb/PLA NFs were electrospun in different formulations to optimize the formulation parameters. The optimized formulation was then investigated for its enhanced in vivo effect. Results: Optimized nanofiber diameters ranged from 459 ± 173 to 668 ± 148 nm, possessing bead-free morphology confirmed by SEM and satisfactory mechanical properties. EMPA was successfully well-dispersed in the polymer matrix as evidenced by FTIR, XRD, and drug content. The optimized NFs displayed a hydrophilic surface (contact angle < 90°), and biphasic drug release with sustained EMPA liberation (84.98% over 24 h). In vivo, buccal EMPA-Cs/Fb/PLA NFs in an AlCl3-induced AD rat model significantly reduced brain-amyloid-β, phosphorylated tau, IL-1β, and AGER expression by 2.88-, 2.64-, 2.87-, and 2.50-fold, respectively, compared to positive controls, and improved locomotor activity (1.86-fold) and cognitive performance (T-maze) (4.17-fold). Compared to pure EMPA, the nanofiber formulation achieved further reductions in amyloid-β (1.78-fold), p-tau (1.42-fold), IL-1β (1.89-fold), and AGER (1.38-fold), with efficacy comparable to memantine. Histopathological examination revealed preservation of the hippocampal neuronal structure. Conclusions: The findings suggest EMPA-loaded Cs/Fb/PLA NFs as a promising non-invasive, sustained-release buccal delivery platform for AD therapy, offering multimodal neuroprotection through modulation of the Aβ–AGER–p-tau axis.

1 January 2017 in Journal of The Arab Society for Medical Research
Verified
Journal Article
Open access
MSMarwa EL Araby Shabana
Marwa EL Araby Shabana
NANaglaaF Abbas
NaglaaF Abbas
FHFahimaM Habib
FahimaM Habib
ASAhmedA Soliman
AhmedA Soliman
Tastatic process. This step in metastasis of malignant cells requires the association of proteolytic catalysts that degrade protein segment of the extracellular matrix. Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) are the members of degrading enzymes required in tumor advancement, invasion, and metastasis. This work aims to examine the utility of MMPs in breast carcinoma to assess their usefulness in growth, invasion, and metastasis. Patients and methods A total of 60 samples of cases of breast cancer with positive and negative lymph nodes were collected randomly as paraffin blocks which was previously prepared material. The samples from the cases were immunostained for MMP-2 and MMP-9, and their expression was correlated with various clinicopathological parameters. Results Most cases of cancer were presented in the age group 51–60 years. The most common type was invasive duct carcinoma Not Otherwise Specified (NOS), representing 70% of cases. Overall, 51 (85%) cases were positive for MMP-2 whereas 54 (90%) cases were positive for MMP-9. Presence of MMP-2 and MMP-9 in peritumoral stroma was in the ratio of 60 and 64%, respectively. Both markers were significantly elevated in malignant tissues of patient with lymph node metastasis as compared with those without lymph node metastasis (P=0.029 and 0.048, respectively). The expression of MMP-2 and MMP-9 increased with advanced clinical staging and grading (P=0.015 and 0.011). Conclusion Expression of MMP-2 and MMP-9 in breast cancer is closely correlated with positive lymph node, high histological grade, and advanced clinical stage. More studies with a huge sample size are needed to assess the prognostic role of MMPs in breast cancer. The use of MMP inhibitors as an adjuvant treatment for breast carcinoma is recommended....

1 January 2021 in Egyptian Journal of Pathology
Verified
Journal Article
Open access
MSMarwa EL Araby Shabana
Marwa EL Araby Shabana
ADAmina A. Gamal El Din
Amina A. Gamal El Din
SAShady Anis
Shady Anis
ZEZahraa Sh. Elalfy
Zahraa Sh. Elalfy
TRThanaa M. Rabah
Thanaa M. Rabah
NKNoura Kamel
Noura Kamel
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. It accounts for 15–20% of all types of breast cancer. Many research studies have begun to study the role of immunotherapy markers for possible TNBC treatment, among which are poly (ADP-ribose) polymerase 1 (PARP-1) and androgen receptors (ARs). Aim: The aim of the study was to examine the immunohistochemical expression of each of PARP-1 and ARs in TNBC for their possible use as target therapy. Patients and methods: A total of 52 paraffin blocks of TNBC cases were received from private laboratories with known status of detailed history. The expression of each of PARP-1 and ARs was studied by immunohistochemistry. Nuclear intensity and area percentage of the markers were evaluated using an image analysis system. Result: PARP-1 was highly expressed in a large percentage of TNBC (91%). There was a significant relation between PARP-1 expression and stage of the tumor, with no significant relation with other clinicopathological parameters. AR expression was high in 29% of cases, with significant relation between its expression and each of grade of the tumor and lymph node metastasis. Morphometric results showed a specific positive correlation between Ki-67 proliferation and different AR statuses and also showed a positive significant correlation between Ki-67 and each of PARP-1 and AR immunohistochemical intensity and also degree of AR expression. There was a significant positive correlation between PARP-1 immunohistochemical intensity and AR immunohistochemical intensity. Conclusion: The current study showed a high positive immunohistochemical expression of PARP-1 in a large percentage of TNBC cases (91%) and AR immunohistochemical expression in a substantial number of cases (29%), as well as a significant positive correlation between PARP-1 immunohistochemical intensity and AR immunohistochemical intensity, which support that both PARP-1 inhibitor and AR antagonist may be potential therapy options in TNBC treatment. The significant correlation noticed in the study between AR-negative immunohistochemical expression of TNBC cases and presence of lymph node metastasis may suggest the possible future role of AR receptors as a prognostic factor in TNBC cases.

29 December 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Open access
PDF file
WEWalaa A. El-dakroury
Walaa A. El-dakroury
ASAbdelrahman R. Said
Abdelrahman R. Said
GAGihan F. Asaad
Gihan F. Asaad
HAHeba M. I. Abdallah
Heba M. I. Abdallah
MSMarwa EL Araby Shabana
Marwa EL Araby Shabana
SAShaza Hussiny Aly
Shaza Hussiny Aly
Lornoxicam-loaded chitosan-coated Litsea lipid nanocarriers (LRX-CS-LLCs) were developed as an innovative oral delivery system, combining the synergistic anti-inflammatory effects of Litsea cubeba oil with the mucoadhesive properties of chitosan. The GC/MS analysis of Litsea cubeba oil identified α -citral (47.56%), β -citral (26.86%), and D -limonene (14.00%). Various LRX-loaded LLCs were prepared and optimized. Fourier transform-infrared (FTIR) and differential scanning calorimetry (DSC) confirmed its structural integrity. The optimized (LRX-CS-LLCs) exhibited a particle size of 165.4 ± 6.3 nm, zeta potential of + 26.3 ± 3.2 mV, and entrapment effectiveness of 98.2%. In vitro release followed a controlled kinetic profile. In vivo, LRX-CS-LLCs significantly reduced carrageenan-induced paw edema (77 ± 1.86% inhibition) and PGE2, COX-2, and TNF-α levels by 4.4-, 3.6-, and 3-fold, respectively, compared to the positive control group. Histopathological examinations confirmed normal tissue architecture. Notably, LRX-CS-LLCs outperformed pure-LRX, marketed-LRX, and uncoated-LRX-LLCs, emphasizing its promise as an effective oral therapeutic approach for enhanced management of inflammatory conditions.

7 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
RARania Ahmed
Rania Ahmed
HFHadir Farouk
Hadir Farouk
YHYosra A. Hussien
Yosra A. Hussien
MSMarwa EL Araby Shabana
Marwa EL Araby Shabana
MNMaha Nasr
Maha Nasr
Background/Objectives: The clinical efficacy of cyclophosphamide, a commonly used chemotherapeutic drug, is often restricted by off-target neurotoxicity, which is primarily caused by oxidative stress, neuroinflammation, and apoptosis. With the aim of finding natural neuroprotective agents, pterostilbene was investigated in this study, either in conventional form or when solubilized as a nanoemulsion, for its neuroprotective potential against cyclophosphamide-induced neurotoxicity. Methods: Female Wistar rats were orally administered pterostilbene, either in its conventional form (50 mg/kg p.o) or nanoemulsion form (25 and 50 mg/kg p.o), for 15 days. Cyclophosphamide was injected once on day 14 (200 mg/kg ip). Results: Our findings revealed that administering pterostilbene as a nanoemulsion or in its conventional powder form managed to counteract the cyclophosphamide-induced intoxication features via disrupting the oxidative stress–inflammasome–cytokine axis; by upregulating cortical and hippocampal PPAR-γ, Nrf2, HO-1, BCL2 levels and the BCL2/Bax ratio; and downregulating NLRP3, IL-1β, COX-2, Bax and GFAP levels. Further histopathological and immunohistochemical evaluation confirmed the improved neuronal morphology, reduced degeneration and apoptosis, restoration of cortical and hippocampal architecture, and normalization of GFAP expression levels, approaching those of the control group upon treatment with either conventional or nanoformulated pterostilbene. Conclusions: The promising nature of the nanoemulsion formulation, particularly when administered at the high dose level, was evidenced, hence emphasizing the important role of proper formulation of natural bioactives such as pterostilbene in maximizing their therapeutic potential.